<code id='F7ADE2DE84'></code><style id='F7ADE2DE84'></style>
    • <acronym id='F7ADE2DE84'></acronym>
      <center id='F7ADE2DE84'><center id='F7ADE2DE84'><tfoot id='F7ADE2DE84'></tfoot></center><abbr id='F7ADE2DE84'><dir id='F7ADE2DE84'><tfoot id='F7ADE2DE84'></tfoot><noframes id='F7ADE2DE84'>

    • <optgroup id='F7ADE2DE84'><strike id='F7ADE2DE84'><sup id='F7ADE2DE84'></sup></strike><code id='F7ADE2DE84'></code></optgroup>
        1. <b id='F7ADE2DE84'><label id='F7ADE2DE84'><select id='F7ADE2DE84'><dt id='F7ADE2DE84'><span id='F7ADE2DE84'></span></dt></select></label></b><u id='F7ADE2DE84'></u>
          <i id='F7ADE2DE84'><strike id='F7ADE2DE84'><tt id='F7ADE2DE84'><pre id='F7ADE2DE84'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:7954
          A sign of Lilly on the top of its biotechnology center — coverage from STAT
          Adobe

          Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

          In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

          advertisement

          In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays
          Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          The creative science of coining drug names

          GarethCattermole/GettyImagesCialis,Eliquis,Jevtana,Xgeva.Thesedrugnamesmaysoundsilly,buttheprocessof